Cargando…

The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence

Dementia remains an extremely prevalent syndrome among older people and represents a major cause of disability and dependency. Alzheimer’s disease (AD) accounts for the majority of dementia cases and stands as the most common neurodegenerative disease. Since age is the major risk factor for AD, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva-Spínola, Anuschka, Baldeiras, Inês, Arrais, Joel P., Santana, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869403/
https://www.ncbi.nlm.nih.gov/pubmed/35203524
http://dx.doi.org/10.3390/biomedicines10020315
_version_ 1784656489610215424
author Silva-Spínola, Anuschka
Baldeiras, Inês
Arrais, Joel P.
Santana, Isabel
author_facet Silva-Spínola, Anuschka
Baldeiras, Inês
Arrais, Joel P.
Santana, Isabel
author_sort Silva-Spínola, Anuschka
collection PubMed
description Dementia remains an extremely prevalent syndrome among older people and represents a major cause of disability and dependency. Alzheimer’s disease (AD) accounts for the majority of dementia cases and stands as the most common neurodegenerative disease. Since age is the major risk factor for AD, the increase in lifespan not only represents a rise in the prevalence but also adds complexity to the diagnosis. Moreover, the lack of disease-modifying therapies highlights another constraint. A shift from a curative to a preventive approach is imminent and we are moving towards the application of personalized medicine where we can shape the best clinical intervention for an individual patient at a given point. This new step in medicine requires the most recent tools and analysis of enormous amounts of data where the application of artificial intelligence (AI) plays a critical role on the depiction of disease–patient dynamics, crucial in reaching early/optimal diagnosis, monitoring and intervention. Predictive models and algorithms are the key elements in this innovative field. In this review, we present an overview of relevant topics regarding the application of AI in AD, detailing the algorithms and their applications in the fields of drug discovery, and biomarkers.
format Online
Article
Text
id pubmed-8869403
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88694032022-02-25 The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence Silva-Spínola, Anuschka Baldeiras, Inês Arrais, Joel P. Santana, Isabel Biomedicines Review Dementia remains an extremely prevalent syndrome among older people and represents a major cause of disability and dependency. Alzheimer’s disease (AD) accounts for the majority of dementia cases and stands as the most common neurodegenerative disease. Since age is the major risk factor for AD, the increase in lifespan not only represents a rise in the prevalence but also adds complexity to the diagnosis. Moreover, the lack of disease-modifying therapies highlights another constraint. A shift from a curative to a preventive approach is imminent and we are moving towards the application of personalized medicine where we can shape the best clinical intervention for an individual patient at a given point. This new step in medicine requires the most recent tools and analysis of enormous amounts of data where the application of artificial intelligence (AI) plays a critical role on the depiction of disease–patient dynamics, crucial in reaching early/optimal diagnosis, monitoring and intervention. Predictive models and algorithms are the key elements in this innovative field. In this review, we present an overview of relevant topics regarding the application of AI in AD, detailing the algorithms and their applications in the fields of drug discovery, and biomarkers. MDPI 2022-01-29 /pmc/articles/PMC8869403/ /pubmed/35203524 http://dx.doi.org/10.3390/biomedicines10020315 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Silva-Spínola, Anuschka
Baldeiras, Inês
Arrais, Joel P.
Santana, Isabel
The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence
title The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence
title_full The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence
title_fullStr The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence
title_full_unstemmed The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence
title_short The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence
title_sort road to personalized medicine in alzheimer’s disease: the use of artificial intelligence
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869403/
https://www.ncbi.nlm.nih.gov/pubmed/35203524
http://dx.doi.org/10.3390/biomedicines10020315
work_keys_str_mv AT silvaspinolaanuschka theroadtopersonalizedmedicineinalzheimersdiseasetheuseofartificialintelligence
AT baldeirasines theroadtopersonalizedmedicineinalzheimersdiseasetheuseofartificialintelligence
AT arraisjoelp theroadtopersonalizedmedicineinalzheimersdiseasetheuseofartificialintelligence
AT santanaisabel theroadtopersonalizedmedicineinalzheimersdiseasetheuseofartificialintelligence
AT silvaspinolaanuschka roadtopersonalizedmedicineinalzheimersdiseasetheuseofartificialintelligence
AT baldeirasines roadtopersonalizedmedicineinalzheimersdiseasetheuseofartificialintelligence
AT arraisjoelp roadtopersonalizedmedicineinalzheimersdiseasetheuseofartificialintelligence
AT santanaisabel roadtopersonalizedmedicineinalzheimersdiseasetheuseofartificialintelligence